Serum sickness, a reaction characterized by fever, rash, myalgia, and
arthralgia, can occur in patients who receive chimeric monoclonal
antibody therapy. Serum sickness is considered as a rare adverse event
following rituximab therapy. We report a case of serum sickness in a
newly treated patient with rituximab for pemphigus vulgaris.